Floatz Rating
BBB78/100
Confidence
Indicative
Sponsor
Boehringer Ingelheim
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
81High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00751803CT.gov BI 44370 TA in Acute Migraine Attack | — | Completed | — | — | — |
NCT01276977CT.gov Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine | — | Completed | — | — | — |
NCT00385008CT.gov TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine | — | Completed | — | — | — |
NCT00174395CT.gov A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine | — | Completed | — | — | — |
NCT00259649CT.gov Prospective Survey of Menstrual Migraine & Prevention With Eletriptan | — | Completed | — | — | — |
NCT00632385CT.gov Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy | — | Completed | — | — | — |
NCT00634985CT.gov Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs | — | Completed | — | — | — |
NCT01989936CT.gov Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan | — | Completed | — | — | — |
NCT01986270CT.gov Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo | — | Completed | — | — | — |
NCT01986088CT.gov Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT01978496CT.gov Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eletriptan (this asset) | Boehringer Ingelheim | Approved | BBB · 78 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eptinezumab | Stanford University | P4 | BBB |
| Galcanezumab | Stanford University | P4 | BBB |
+42 more in the Migraine Disorder cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eletriptan in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eletriptan-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →